雷替曲塞联合紫杉醇一线治疗晚期胃癌的临床效果分析

Clinical effects of raltitrexed combined with paclitaxel in the first-line treatment of advanced gastric cancer

目的:探讨雷替曲塞联合紫杉醇一线治疗晚期胃癌的临床效果。方法:选择晚期胃癌患者82例随机分为对照组和观察组各41例。对照组采用氟尿嘧啶(5-FU)联合紫杉醇方案治疗,观察组采用雷替曲塞联合紫杉醇方案治疗,21 d为1治疗周期,连续治疗2个周期后对比两组临床疗效、不良反应。结果:化疗后,两组治疗总有效率和控制率比较差异无统计学意义(P=0.142,P=0.284);两组均出现以骨髓毒性和肠道反应为主的毒副反应,且多数为Ⅰ~Ⅱ度,且观察组骨髓毒性和肠道反应发生率低于对照组(P=0.023,P=0.012)。结论:雷替曲塞联合紫杉醇一线治疗晚期胃癌,临床效果显著,且能够降低不良反应的发生率。

Objective:To investigate the clinical effect of raltitrexed combined with paclitaxel on advanced gastric cancer.Methods:Eighty-two patients with advanced gastric cancer were randomly divided into a control group and an observation group.The control group was treated with fluorouracil(5-FU)combined with paclitaxel regimen,and the observation group was treated with raltitrexed combined with paclitaxel regimen for 21 days.After two consecutive cycles,the clinical efficacy and adverse reactions were compared between the two groups.Results:After chemotherapy,there were no significant differences in overall response rate and control rate between the two groups(P=0.142,P=0.284).The adverse reactions were mainly bone marrow toxicity and intestinal reactions in both groups,and most of them belonged to I~II degrees.The incidence of bone marrow toxicity and intestinal reactions was lower in the observation group than the control group(P=0.023,P=0.012).Conclusion:Raltitrexed combined with paclitaxel is effective in the first-line treatment of advanced gastric cancer.